TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01545583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 subcutaneous
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: Administered subcutaneously
Study: NCT03466983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: administered IV
Study: NCT03043443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Natural health product for sleep problems treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose containing pills
Study: NCT04103164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera excel V™ Laser
Description: The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
Study: NCT03946956

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
Study: NCT04055818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
Study: NCT03829553

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: 5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
Study: NCT03735459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient reminders and accountability questionnaires
Description: Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
Study: NCT04092322

Intervention type: DEVICE
Intervention: Actical accelerometers (Philips Respironics)
Description: patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
Study: NCT00741195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
Study: NCT04092322

Intervention type: OTHER
Intervention: PASE
Description: Physical Activity Scale for Elderly
Study: NCT01857076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass surgery
Description: Gastric bypass surgery performed laparoscopically

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ileal transposition with sleeve
Description: Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical
Description: The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
Study: NCT03192501

Intervention type: DRUG
Intervention: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
Description: Choose appropriate targeted drugs according to NGS/IHC results.

Intervention type: DRUG
Intervention: inhibitors, ADC drugs such as tarceva, capmatinib, padcev et al for A/C group.
Description: Choose appropriate targeted drugs according to NGS/IHC results.
Study: NCT00637858

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 5mg
Description: Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 15mg
Description: Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lyc-O-Mato 30mg
Description: Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lycopene capsules (non Lyc-o-mato) 15 mg
Description: Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
Study: NCT04559633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive and behavioral therapy (CBT)
Description: The CBT program is delivered by a multidisciplinary team with 4 half day hospitalization that includes individual, group CBT and education time (2 hours per day delivered by the teacher). Participants have homework to do in their own time at home.~CBT is a manualized program with anxiety psychoeducation, stress management, cognitive restructuration, problem solving techniques, progressive exposure, assertiveness exercises and self-esteem work.
Study: NCT01542255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 1 mg/m2 vinblastine given three times per week administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
Study: NCT00741195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
Study: NCT03538444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham rTMS
Description: Participants will undergo procedures that mimic rTMS, but that are inactive.
Study: NCT01231178

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alginate beverage
Description: The dosage is 3x500ml daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control beverage
Description: The dosage is 3x500ml daily
Study: NCT04860999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The osteopathic manipulations focused on treating the asymmetric postural dysfunction that was identified by the initial functional structural evaluation. The manipulation consisted of typical time-honored osteopathic treatments directed at the identified somatic dysfunction(s). These techniques were clinically directed and include: soft tissue, muscle energy, high velocity low amplitude, low velocity high amplitude as well as facilitated positional release as indicated.
Study: NCT02381028

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human milk and emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of human milk followed by emollient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of emollient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emollient: Apobase creme® (Actavis Norway AS)
Description: Topical application of emollient
Study: NCT03374254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab solution for IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab solution for IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Pembrolizumab solution for IV infusion Q3W
Study: NCT03879629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
Study: NCT03272217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg (flat dose) IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV every 21 days
Study: NCT03150576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 \& 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
Study: NCT03500172

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
Study: NCT00513474

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide
Description: Etoposide as standard of care for myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide as standard of care for myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: methotrexate
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: sirolimus
Description: Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: tacrolimus
Description: Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic hematopoietic stem cell transplantation
Study: NCT03990922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block with ropivacaine
Description: Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral block with saline
Description: Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine
Description: Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patient-controlled analgesia with morphine
Description: Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Study: NCT03088410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: neonatal 4 weeks prophylactic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: neonatal 4 weeks prophylactic
Study: NCT00513474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: OTHER
Intervention: total-body irradiation
Description: Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine
Description: Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Fludarabine 40 mg/m\^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion

Intervention type: DRUG
Group type: OTHER
Intervention: allopurinol
Description: Allopurinol per institutional guidelines
Study: NCT01686633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol 200/25 mcg
Description: Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate/ Vilanterol 100/25 mcg
Description: Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate 100 mcg
Description: Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
Study: NCT01074957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry
Description: Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breath-Stacking Technique
Description: An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
Study: NCT01441310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sentinel node navigation surgery
Description: Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
Study: NCT03500172

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP
Description: Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ICM
Description: Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
Study: NCT01847456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin as nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05076825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic Sliding
Description: Participants supine with their cervical and thoracic spine supported in a forward flexed position. Simultaneous hip and knee flexion will be alternated dynamically with simultaneous hip and knee extension. The therapist will change the arrangement of movement depending on the tissue resistance level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Participent lying supine, the therapist will passively position the subject into the straight leg raise position without discomfort or pain to the point where resistance to movement will be first felt.